CD38 and Miyoshi myopathy: The phase II study of DREAMM -2 (NCT03525678) enrolled 196 previously overtreated R/R MM patients to further evaluate the efficacy and safety of single-agent GSK2857916 in patients refractory to immunomodulators, PIs and refractory and/or intolerant to CD38-targeted monoclonal antibodies.